Eduovisual
Female Reproductive & Breast
Endometrial cancer: presentation and workup
— Median age at diagnosis ~63; postmenopausal predominance (~75% of cases).
— Rising incidence, paralleling obesity and metabolic syndrome trends.
— Black women have lower incidence but higher mortality, often from aggressive non-endometrioid (serous, clear cell, carcinosarcoma) histologies.
— Type I (endometrioid, ~80%): estrogen-driven, preceded by hyperplasia, generally low-grade, better prognosis. Linked to obesity, anovulation, unopposed estrogen.
— Type II (serous, clear cell, carcinosarcoma): estrogen-independent, p53 mutations, arises in atrophic endometrium, presents at higher stage.
— Any postmenopausal bleeding — endometrial cancer until proven otherwise (≈10% PMB cases are malignant).
— Perimenopausal woman with intermenstrual bleeding, menorrhagia, or AUB age ≥45.
— Women <45 with persistent AUB plus risk factors (obesity, PCOS, chronic anovulation, tamoxifen, Lynch syndrome, nulliparity, diabetes, late menopause >55).
— Atypical glandular cells (AGC) on cervical cytology → mandates endometrial evaluation in women ≥35 or with risk factors.
— Incidental thickened endometrium on pelvic imaging in a symptomatic patient.
Board pearl: Combined OCPs, multiparity, smoking, and progestin-containing IUDs are protective. Lynch syndrome carries up to a 40–60% lifetime endometrial cancer risk, often presenting earlier (40s) — counsel for surveillance or risk-reducing hysterectomy after childbearing.
— Postmenopausal bleeding (PMB): any bleeding ≥12 months after the last menstrual period. Even a single episode of spotting warrants workup.
— Premenopausal: intermenstrual bleeding, heavy/prolonged menses, or AUB unresponsive to standard management.
— Bloody or watery, foul-smelling vaginal discharge (especially in elderly with cervical stenosis → pyometra/hematometra).
— Pelvic pain, pressure, bloating (advanced or large tumors).
— Weight loss, early satiety, abdominal distension (intraperitoneal spread, especially serous histology mimicking ovarian cancer).
— Lower extremity edema or DVT (pelvic mass effect, hypercoagulability).
— Asymptomatic — abnormal Pap with endometrial cells in woman ≥45 or AGC at any age.
— Bleeding characterization: onset, duration, pattern, volume, relation to intercourse.
— Menopausal status and time since last menses; HRT use (unopposed estrogen is a red flag).
— Medications: tamoxifen (4–7× risk after 5 years), exogenous estrogen, anticoagulants (can unmask bleeding).
— OB/Gyn: parity, infertility, PCOS, prior endometrial biopsy/hyperplasia.
— Comorbidities: obesity (BMI), diabetes, hypertension ("corpus cancer triad" — classic but not specific).
— Family history: Lynch syndrome (colon, endometrial, ovarian, gastric, urothelial in 1st-degree relatives <50), Cowden, breast/ovarian.
— Prior cancer therapy: pelvic radiation history.
Step 3 management: A postmenopausal woman on tamoxifen for breast cancer with new spotting → do not dismiss as tamoxifen effect. Proceed directly to endometrial sampling; routine screening TVUS in asymptomatic tamoxifen users is not recommended (high false-positive rate from subepithelial stromal changes).
Key distinction: PMB warrants tissue sampling regardless of volume; "just a little spotting" is the classic distractor in board stems where students choose reassurance and miss the diagnosis.
— Often well-appearing; obesity is the most common visible finding (BMI ≥30 in ~50%).
— Cachexia, pallor, or lymphadenopathy suggests advanced disease.
— Assess performance status (ECOG) — drives surgical candidacy and chemotherapy tolerance.
— Most patients are hemodynamically stable; heavy AUB rarely causes acute instability but can produce chronic iron-deficiency anemia.
— Tachycardia + orthostasis in a bleeding patient → check CBC, type & screen, consider transfusion.
— Fever + uterine tenderness in elderly with cervical stenosis → suspect pyometra (can mimic or accompany cancer).
— Palpable suprapubic/pelvic mass suggests large uterus or extrauterine spread.
— Ascites or omental caking → advanced (often serous) disease; Sister Mary Joseph nodule (periumbilical) is a rare but classic finding.
— Hepatomegaly → metastatic disease.
— Speculum: identify source of bleeding (uterine vs cervical vs vaginal vs vulvar vs urethral vs rectal — a board favorite).
— Inspect cervix for visible tumor, polyp, friability; perform Pap if not current.
— Bimanual: uterine size, mobility, tenderness, adnexal masses. Fixed/immobile uterus suggests parametrial invasion.
— Rectovaginal exam: parametrial nodularity, posterior cul-de-sac masses, rectal mucosal involvement.
CCS pearl: On the CCS case, after focused history for PMB, order "complete physical exam" including pelvic and rectovaginal exam before ordering labs/imaging. Skipping the pelvic and going straight to ultrasound costs points and delays diagnosis.
Board pearl: Always confirm the anatomic source of bleeding. A common distractor: an elderly woman with "vaginal bleeding" actually has hematuria or hemorrhoidal bleeding — speculum and rectal exams clarify before invasive uterine workup.
— (A) Transvaginal ultrasound (TVUS) as initial triage in postmenopausal women with PMB.
— (B) Endometrial biopsy (EMB) as the initial test, particularly when clinical suspicion is high, patient has risk factors, or imaging access is limited.
— ACOG endorses either; direct EMB is preferred if any concern for non-endometrioid histology, recurrent bleeding, or persistent symptoms after a "thin stripe."
— Endometrial thickness (ET) ≤4 mm → negative predictive value >99% for endometrioid cancer; can observe if bleeding resolves.
— ET >4 mm, focal lesion, heterogeneity, or recurrent bleeding → tissue sampling mandatory.
— TVUS is not reliable in premenopausal women (cyclic variation) — go straight to sampling.
— Tamoxifen users: TVUS unreliable due to subepithelial changes; sample if symptomatic.
— CBC (anemia from chronic bleeding), type & screen if heavy.
— Pregnancy test (β-hCG) in any reproductive-age woman before invasive workup.
— TSH, prolactin, coagulation studies if AUB workup in premenopausal patient.
— Basic metabolic panel, LFTs, glucose/A1c (comorbidity assessment for surgical planning).
— CA-125 — not diagnostic, but elevated levels (especially in serous/clear cell) predict extrauterine disease and assist surveillance.
Step 3 management: Postmenopausal woman, single episode of spotting, TVUS ET = 3 mm → reassure and instruct to return if recurrence; recurrent bleeding despite a thin stripe mandates tissue sampling (sampling error and serous cancers can present with thin endometrium).
Board pearl: ET cutoff of 4 mm applies only to postmenopausal women with bleeding. Asymptomatic incidental thickening has no validated cutoff — manage based on symptoms and risk factors.
— First-line tissue sampling; sensitivity ~90% for endometrial cancer in postmenopausal women.
— Limitations: focal lesions, cervical stenosis, inadequate sample (~5–15%), pain intolerance.
— A negative EMB with persistent bleeding does not exclude cancer — proceed to hysteroscopy with D&C.
— Gold standard when EMB nondiagnostic, inadequate, or clinical suspicion remains.
— Allows directed biopsy of focal lesions; identifies polyps and submucosal pathology.
— Theoretical concern for tumor cell dissemination via distention media — clinical significance is minimal and does not change practice.
— Histologic type: endometrioid vs serous vs clear cell vs carcinosarcoma vs mucinous vs mixed.
— FIGO grade (1–3) for endometrioid; serous/clear cell are inherently high-grade.
— Myometrial invasion depth (on hysterectomy specimen), LVSI, cervical/adnexal involvement.
— Molecular classification (TCGA, increasingly board-relevant): POLE-ultramutated (excellent prognosis), MSI-high/MMR-deficient, copy-number low, copy-number high (p53-mutant; poor prognosis).
— Universal MMR/MSI testing on all endometrial cancers to screen for Lynch syndrome — refer to genetics if abnormal.
— Endometrial cancer is surgically staged: TAH-BSO, peritoneal washings, ± sentinel lymph node mapping (replacing routine pelvic/para-aortic lymphadenectomy in low-risk disease).
— MRI pelvis: evaluates myometrial invasion depth, cervical stromal involvement — useful if fertility-sparing considered or surgical planning.
— CT chest/abdomen/pelvis or PET-CT: indicated for high-grade, serous, clear cell, carcinosarcoma, or clinically advanced disease to detect nodal/distant metastases.
Key distinction: Endometrial hyperplasia with atypia (EIN) carries a 25–40% concurrent cancer risk on hysterectomy specimen → definitive treatment is hysterectomy, not just progestin therapy (unless fertility-sparing in a highly selected patient).
— Stage I: confined to uterus (IA <50% myometrial invasion; IB ≥50%).
— Stage II: cervical stromal invasion.
— Stage III: local/regional spread (adnexa, vagina, parametria, pelvic/para-aortic nodes).
— Stage IV: bladder/bowel mucosa or distant metastases.
— Low risk: stage IA, grade 1–2 endometrioid, no LVSI → surgery alone, excellent prognosis (5-yr survival >95%).
— Intermediate risk: stage IA grade 3, IB grade 1–2, or LVSI → vaginal brachytherapy.
— High-intermediate: IB grade 3, II, or substantial LVSI → external beam RT ± brachytherapy.
— High risk: stage III, serous, clear cell, carcinosarcoma → chemotherapy (carboplatin + paclitaxel) ± RT.
— Advanced/metastatic: systemic therapy ± palliative measures.
— Total hysterectomy + bilateral salpingo-oophorectomy (minimally invasive preferred when feasible) with peritoneal washings and sentinel lymph node mapping.
— Omentectomy added for serous, clear cell, carcinosarcoma.
— Gynecologic oncology referral for any biopsy-proven cancer, suspected advanced disease, or non-endometrioid histology.
— Criteria: grade 1 endometrioid, stage IA, no myometrial invasion on MRI, no LVSI, desires fertility, willing to undergo intensive surveillance.
— Treatment: high-dose progestin (megestrol, medroxyprogesterone) or levonorgestrel IUD, with EMB every 3–6 months.
— Definitive hysterectomy after childbearing completed.
Step 3 management: A 65-year-old with biopsy-confirmed grade 1 endometrioid cancer → refer to gynecologic oncology for surgical staging — do not perform a simple hysterectomy in the community setting because of sentinel node mapping and washings requirements.
Board pearl: Molecular classification is increasingly driving adjuvant decisions — POLE-mutated tumors may be observed; p53-mutant tumors require chemotherapy regardless of stage.
— Carboplatin + paclitaxel every 21 days × 6 cycles — backbone for high-risk, stage III/IV, recurrent, and serous/clear cell histologies.
— Monitor for neuropathy (paclitaxel), myelosuppression, hypersensitivity, nephrotoxicity (carboplatin dosed by AUC using Calvert formula — adjust for renal function).
— Indications: low-grade endometrioid, hormone-receptor positive, recurrent or metastatic disease; fertility-sparing primary therapy; medically inoperable patients.
— Options: medroxyprogesterone acetate, megestrol acetate, levonorgestrel IUD, aromatase inhibitors (letrozole) in postmenopausal, tamoxifen alternating with progestins.
— Side effects: VTE risk, weight gain, fluid retention, breakthrough bleeding.
— Pembrolizumab + lenvatinib for advanced/recurrent disease after platinum failure.
— Pembrolizumab or dostarlimab monotherapy for MSI-H / dMMR advanced disease — dramatic responses.
— Recent NEJM trials (RUBY, GY018) support adding immunotherapy to first-line carboplatin/paclitaxel in advanced/recurrent disease, especially dMMR tumors.
— Monitor for immune-related adverse events: thyroiditis, pneumonitis, colitis, hepatitis, hypophysitis.
— Trastuzumab added to carbo/paclitaxel for HER2-positive uterine serous carcinoma — practice-changing.
— PARP inhibitors and antibody-drug conjugates (e.g., trastuzumab deruxtecan) under active investigation.
— VTE prophylaxis perioperatively (extended 4-week LMWH after major pelvic oncologic surgery).
— Bone health surveillance with aromatase inhibitor use.
Board pearl: All endometrial cancers should undergo MMR/MSI testing — it identifies Lynch syndrome (cascade testing for family) AND predicts response to checkpoint inhibitors. A single test with dual implications is high-yield exam material.
— Total hysterectomy + bilateral salpingo-oophorectomy (TH/BSO), peritoneal washings, sentinel lymph node (SLN) mapping with indocyanine green (ICG) cervical injection.
— Minimally invasive (laparoscopic or robotic) approach is standard — LAP2 trial demonstrated equivalent oncologic outcomes with reduced morbidity.
— Omentectomy + comprehensive peritoneal biopsies for serous, clear cell, carcinosarcoma.
— Para-aortic node sampling for high-risk histology or grossly enlarged nodes.
— Has largely replaced full pelvic/para-aortic lymphadenectomy in apparent uterine-confined disease.
— Reduces lymphedema risk while preserving staging accuracy.
— Failed mapping → side-specific lymphadenectomy.
— Vaginal brachytherapy (VBT): reduces vaginal cuff recurrence in intermediate-risk disease; few systemic side effects.
— External beam radiation (EBRT): for stage II–III, positive nodes, or substantial extrauterine disease.
— Side effects: radiation cystitis, proctitis, vaginal stenosis (counsel re: dilator use), bowel obstruction, secondary malignancy.
— Medically inoperable (severe obesity, cardiopulmonary disease): primary radiation (EBRT + brachytherapy) or hormonal therapy.
— Recurrent vaginal cuff disease: salvage with radiation if not previously irradiated → high cure rates.
— Pelvic exenteration: rare; reserved for central pelvic recurrence after prior RT with no distant disease.
— Weight management, glycemic control (A1c <8% ideally), VTE risk assessment, cardiac/pulmonary clearance.
— Pneumococcal and influenza vaccines updated; smoking cessation counseling.
CCS pearl: On a CCS case, after biopsy confirmation, the order set is: gyn-onc consult → CT C/A/P (if high-risk histology) → preoperative labs/EKG → anesthesia evaluation → schedule TH/BSO with SLN → perioperative VTE prophylaxis. Forgetting extended postoperative LMWH (4 weeks) is a common point loss.
— Assess frailty (e.g., Fried criteria, G8 screening tool) — predicts surgical morbidity better than chronologic age.
— Comprehensive geriatric assessment: cognition, functional status, polypharmacy, nutrition, falls, social support.
— Surgery is generally well-tolerated in fit elderly; minimally invasive approach is particularly beneficial (reduced ileus, faster ambulation, lower DVT risk).
— Consider vaginal hysterectomy with BSO in select frail patients with low-grade, low-stage disease.
— Medically inoperable elderly: definitive radiation or levonorgestrel IUD/progestin therapy for low-grade disease — both yield reasonable disease control.
— Carboplatin dosed by Calvert formula (AUC × [GFR + 25]); inherently adjusts for renal function and age.
— Paclitaxel — increased neuropathy and myelosuppression; consider dose reduction or weekly schedule.
— Growth factor support (pegfilgrastim) more often needed.
— Carboplatin does not require dose adjustment beyond AUC formula; cisplatin avoided if CrCl <60.
— Avoid NSAIDs perioperatively in CKD; use acetaminophen and judicious opioids for pain control.
— Contrast imaging: assess eGFR; hydrate appropriately; use iodinated contrast cautiously if eGFR <30.
— Paclitaxel is hepatically metabolized — reduce dose in moderate-severe dysfunction.
— Monitor LFTs during immunotherapy; immune hepatitis can occur at any time.
— Hormonal therapy (megestrol) generally well-tolerated but monitor for fluid retention and VTE.
— Surgical menopause in younger women → discuss HRT carefully (generally avoided in hormone-sensitive cancers).
— DEXA screening, calcium/vitamin D, fall prevention.
Step 3 management: A frail 82-year-old with stage I grade 1 endometrioid cancer and severe COPD/CHF declines surgery → offer levonorgestrel IUD or oral progestin therapy with serial imaging/biopsy; alternatively, primary radiation. Document shared decision-making explicitly.
— Risk factors: PCOS, chronic anovulation, obesity, Lynch syndrome, Cowden syndrome, tamoxifen use.
— Workup any premenopausal patient ≥45 with AUB, or <45 with persistent AUB, obesity, or risk factors — proceed directly to endometrial biopsy (TVUS unreliable due to cyclic variation).
— Always check β-hCG before invasive procedures.
— Criteria: grade 1 endometrioid, no myometrial invasion on MRI, no LVSI, strong fertility desire, agreement to intensive surveillance and definitive hysterectomy after childbearing.
— Treatment: levonorgestrel IUD (preferred) ± oral megestrol/medroxyprogesterone.
— Endometrial sampling every 3–6 months; complete response in ~70% but recurrence common.
— Refer to reproductive endocrinology; pursue pregnancy promptly upon response.
— Germline mutations in MLH1, MSH2, MSH6, PMS2, or EPCAM.
— Lifetime endometrial cancer risk 40–60%; ovarian risk 10–15%; colon risk 50–80%.
— Universal tumor MMR/MSI testing on all endometrial cancers; abnormal results → genetics referral and germline testing.
— Surveillance: annual endometrial biopsy and TVUS starting age 30–35; risk-reducing TH/BSO after childbearing (typically by age 40–45).
— Concurrent colonoscopy every 1–2 years starting age 20–25.
— Endometrial cancer during pregnancy is extraordinarily rare; bleeding in pregnancy is virtually never endometrial cancer — pursue obstetric causes first.
— Consider Lynch, Cowden (PTEN), and obesity-related anovulation; cancer is rare but EIN/atypical hyperplasia occurs.
Board pearl: A 38-year-old woman with grade 1 endometrioid cancer and a sister who had colon cancer at 42 → test the tumor for MMR/MSI first; if abnormal, send germline testing for Lynch. This single decision affects her, her children, and her siblings — classic Step 3 ethics/genetics overlap.
— Heavy/persistent vaginal bleeding → iron deficiency anemia, occasional transfusion need.
— Pyometra/hematometra in elderly with cervical stenosis — may present as fever, leukocytosis, lower abdominal pain.
— VTE/PE: endometrial cancer is highly thrombogenic; obesity and surgery compound risk.
— Ureteral obstruction / hydronephrosis from bulky pelvic or nodal disease.
— Bowel obstruction in advanced/recurrent disease, especially serous histology with peritoneal spread.
— Malignant ascites or pleural effusion in stage IV.
— Bleeding, infection, ureteral or bladder injury (~1%), bowel injury, VTE.
— Lymphocele/lymphedema (reduced with SLN approach vs full lymphadenectomy).
— Vaginal cuff dehiscence — present with bleeding, discharge, or evisceration after intercourse; surgical emergency.
— Early: cystitis, proctitis, diarrhea, fatigue, dermatitis.
— Late: vaginal stenosis (vaginal dilator therapy is standard counseling), chronic radiation enteritis, fistula formation, insufficiency fractures, second malignancies.
— Myelosuppression, peripheral neuropathy, alopecia, hypersensitivity, nephrotoxicity, ototoxicity.
— Febrile neutropenia → empiric broad-spectrum antibiotics within 1 hour.
— Thromboembolism, weight gain, fluid retention, mood changes, breakthrough bleeding, hyperglycemia.
— Thyroid dysfunction (most common), pneumonitis, colitis, hepatitis, hypophysitis, type 1 diabetes, adrenal insufficiency. Treat with corticosteroids; permanent hormone replacement often needed for endocrinopathies.
— Sexual dysfunction post-surgery/radiation, body image, surgical menopause symptoms, financial toxicity.
Step 3 management: Postoperative day 14 patient calls with calf swelling and pleuritic chest pain → obtain CT pulmonary angiogram (do not wait for D-dimer in high-pretest-probability oncology patient) and start therapeutic LMWH empirically.
— Any biopsy-confirmed endometrial cancer — improves staging, surgical outcomes, and survival (level I evidence).
— Atypical endometrial hyperplasia (EIN) — high concurrent cancer rate (25–40%).
— Complex cases: morbid obesity, severe comorbidities, fertility-sparing requests, recurrent disease.
— High-risk histologies (serous, clear cell, carcinosarcoma).
— Genetics — for MMR-deficient tumors, family history meeting Lynch/Cowden criteria, or onset <50.
— Medical oncology — co-management for adjuvant chemotherapy in high-risk/advanced disease.
— Radiation oncology — adjuvant or definitive radiation planning.
— Cardiology / pulmonology — preoperative optimization in high-comorbidity patients.
— Palliative care — symptom management in advanced disease; early integration improves QOL.
— Outpatient workup is appropriate for most PMB evaluations.
— Inpatient admission indicated for:
— Hemodynamically significant bleeding requiring transfusion or uterine packing.
— Acute urinary obstruction with AKI → urology for nephrostomy or stent.
— Bowel obstruction.
— Febrile neutropenia, severe sepsis, suspected pyometra with systemic signs.
— Acute VTE/PE in unstable patient.
— Severe pain or symptom crisis in advanced disease.
— Hemodynamic instability requiring vasopressors, mechanical ventilation, massive transfusion, or post-operative complications (anastomotic leak, hemorrhagic shock).
— Clear handoff between gyn-onc surgeon, medical oncologist, radiation oncologist, and primary care.
— Survivorship care plan documenting treatment received, surveillance schedule, late effects, and PCP responsibilities.
CCS pearl: When the case states "biopsy shows grade 2 endometrioid adenocarcinoma," the very next move is consult gynecologic oncology — not "schedule hysterectomy." Specialty referral itself is a scorable action.
— Common cause of PMB and AUB; benign in most cases but can harbor malignancy (~3–5% in postmenopausal).
— Diagnose with TVUS, SIS, or hysteroscopy; treat symptomatic or postmenopausal polyps with hysteroscopic resection.
— Without atypia (benign): progestin therapy (oral or LNG-IUD); ~5% progression to cancer.
— With atypia / EIN: ~25–40% concurrent cancer → hysterectomy preferred; fertility-sparing with LNG-IUD in select patients.
— Most common cause of PMB overall; thin endometrial stripe on TVUS.
— Treat with topical vaginal estrogen after cancer excluded.
— Premenopausal AUB more often; submucosal fibroids cause heavy bleeding.
— Rare to cause new PMB — new bleeding postmenopause warrants malignancy workup regardless of known fibroids.
— Heavy menstrual bleeding and dysmenorrhea in premenopausal women; globular tender uterus.
— Cervical cancer, polyps, cervicitis — speculum exam differentiates from uterine source.
— Atrophic vaginitis, vulvar cancer, lichen sclerosus, trauma.
— Uterine sarcoma (leiomyosarcoma, endometrial stromal sarcoma): rapidly enlarging uterine mass, often postmenopausal; preoperative diagnosis difficult.
— Ovarian cancer: may present with AUB if metastatic to endometrium or hormone-secreting (granulosa cell).
— Fallopian tube cancer: rare; classic triad of watery discharge, pelvic pain, adnexal mass ("hydrops tubae profluens").
— Ectopic, miscarriage, gestational trophoblastic disease — always check β-hCG.
Key distinction: A new pelvic mass with PMB and elevated CA-125 could be advanced endometrial or primary ovarian cancer with endometrial metastasis. Endometrial biopsy plus pelvic imaging (often MRI) clarifies the primary site, which guides surgical approach.
— Hematuria from urothelial carcinoma, cystitis, stones — confirmed on speculum exam (blood at urethral meatus) and urinalysis.
— Urethral caruncle in postmenopausal women — friable urethral lesion bleeding with wiping.
— Hemorrhoidal or anorectal bleeding misinterpreted as vaginal — rectal exam and anoscopy distinguish.
— Colorectal cancer (relevant in Lynch syndrome — concurrent risk).
— Diverticular bleeding (typically painless, large volume).
— Warfarin, DOACs, antiplatelets — can unmask underlying pathology; bleeding on anticoagulation still requires workup for malignancy in PMB.
— Thrombocytopenia, von Willebrand disease (especially in adolescents with heavy menses).
— Liver disease with coagulopathy.
— Thyroid dysfunction — hypothyroidism causes menorrhagia, hyperthyroidism causes oligomenorrhea.
— Hyperprolactinemia — oligo/amenorrhea, galactorrhea.
— PCOS — anovulatory bleeding (also raises cancer risk).
— Adrenal/ovarian androgen-secreting tumors — virilization plus AUB.
— Tamoxifen — both endometrial cancer risk and benign polyps/hyperplasia.
— Unopposed estrogen HRT.
— Anticoagulation.
— Forgotten retained IUD or pessary causing erosion.
— Recent procedures (LEEP, D&C).
— Endometritis (postpartum, post-procedure), PID, tuberculosis (in endemic areas) — fever, tenderness.
— Sexual assault, retained foreign object — particularly relevant in pediatric or cognitively impaired patients.
Board pearl: Anticoagulated postmenopausal woman with vaginal bleeding is a classic distractor. Do not attribute bleeding to warfarin/DOAC alone — proceed with standard endometrial cancer workup. Anticoagulation unmasks, it does not cause, endometrial pathology.
— Low risk → observation.
— Intermediate → vaginal brachytherapy.
— High-intermediate → EBRT ± brachytherapy.
— High risk / advanced → carboplatin + paclitaxel × 6 cycles ± radiation ± immunotherapy.
— HER2+ serous → add trastuzumab.
— dMMR/MSI-H advanced → checkpoint inhibitor inclusion.
— Vasomotor symptoms common after surgical menopause in younger patients.
— Estrogen-containing HRT is generally avoided in hormone-receptor-positive endometrial cancer survivors, especially high-risk histology.
— Non-hormonal options: SSRIs/SNRIs (venlafaxine, paroxetine — avoid paroxetine with tamoxifen), gabapentin, clonidine, oxybutynin, CBT.
— Vaginal atrophy: non-hormonal moisturizers/lubricants; low-dose vaginal estrogen may be considered in select low-risk survivors with shared decision-making.
— Surgical menopause and aromatase inhibitor therapy accelerate bone loss.
— DEXA scan at baseline and periodically; calcium 1200 mg/day + vitamin D 800–1000 IU/day; weight-bearing exercise; bisphosphonates if osteoporosis develops.
— Shared risk factors (obesity, diabetes, HTN) with cancer; aggressive primary care management improves both survival and recurrence-free survival.
— Weight loss interventions, lifestyle counseling, statin/antihypertensive optimization.
— Influenza annually, COVID-19 boosters, pneumococcal series, shingles, HPV (if eligible).
— Age-appropriate cancer screening including colonoscopy intensified in Lynch survivors.
— Vaginal dilator therapy after pelvic radiation.
— Counsel on dyspareunia, libido changes; refer to sexual health specialists when needed.
Step 3 management: Endometrial cancer survivor at 6 months reports severe hot flashes affecting sleep and function → start venlafaxine or gabapentin as first-line non-hormonal therapy; reserve hormonal therapy for refractory low-risk survivors after multidisciplinary discussion.
— Years 1–2: history, physical with pelvic exam every 3–6 months.
— Years 3–5: every 6–12 months.
— >5 years: annually.
— High-risk histology may warrant more frequent intervals.
— Symptom review: vaginal bleeding/discharge, pelvic pain, abdominal pain/bloating, weight loss, urinary or bowel symptoms, lower extremity edema, cough, dyspnea.
— Comprehensive pelvic exam including speculum and bimanual.
— Routine vaginal cytology is NOT recommended — does not improve detection of recurrence.
— Routine imaging (CT, MRI, PET) is NOT recommended in asymptomatic patients with low-risk disease — order based on symptoms or exam findings.
— CA-125 — only if elevated at diagnosis (typically serous/clear cell); use as trend marker.
— ~70–80% of recurrences occur within 2–3 years of treatment.
— Most common sites: vaginal cuff (salvageable with RT if not previously irradiated), pelvis, distant (lung, abdomen, bone).
— Isolated vaginal recurrence in previously unirradiated patient → high cure rate with salvage radiation (~50–70%).
— Report any vaginal bleeding, discharge, new pelvic pain, leg swelling, persistent cough, unintended weight loss.
— Lifestyle: weight loss (each 5% BMI reduction lowers recurrence risk); physical activity ≥150 min/week; smoking cessation; alcohol moderation.
— Sexual health support; vaginal dilator use post-radiation.
— Lymphedema awareness if lymphadenectomy performed.
— Cascade genetic testing for first-degree relatives if Lynch syndrome identified.
— Encourage relatives' age-appropriate cancer screening.
Board pearl: A common Step 3 trap: ordering "annual CT scans" or "Pap smears every 6 months" for endometrial cancer surveillance. Neither is standard — surveillance is clinical (history and pelvic exam), with imaging or labs only as symptom-driven.
— Discuss alternatives (rare in cancer setting, but applicable for atypical hyperplasia or fertility-sparing candidates).
— Surgical menopause implications in premenopausal patients — vasomotor symptoms, osteoporosis, cardiovascular risk, sexual function.
— Risks of laparoscopic vs open approach; bowel/bladder/ureter injury; VTE; conversion to laparotomy.
— Document discussion of fertility loss explicitly in premenopausal patients; offer fertility preservation referral if appropriate before treatment.
— Universal MMR testing identifies Lynch syndrome — counsel patient about implications for siblings, children, parents.
— Cascade testing in relatives is voluntary; respect autonomy if a relative declines.
— Privacy: results affect insurance considerations (GINA protects health insurance and employment but not life, disability, or long-term care insurance — important counseling point).
— Black women experience higher mortality despite lower incidence — recognize systemic factors (delayed diagnosis, access to gyn-onc, undertreatment of aggressive histologies).
— Ensure equitable access to gyn-onc referral, clinical trials, and genetic services.
— Postoperative discharge: explicit instructions on VTE prophylaxis (extended 4-week LMWH), wound care, vaginal cuff precautions (no intercourse/tampons for 6 weeks), signs of complications.
— Clear handoff between surgeon, radiation oncologist, medical oncologist, and primary care; shared electronic survivorship care plan.
— Medication reconciliation, especially anticoagulants and hormonal therapies.
— Advanced/recurrent disease: discuss goals of care, code status, hospice eligibility.
— Early palliative care integration improves QOL and may extend survival.
— Suspected elder abuse in bleeding workup of cognitively impaired patient — report per state law.
Step 3 management: A 42-year-old with newly diagnosed grade 1 endometrioid cancer who desires future pregnancy → before any hysterectomy, document a multidisciplinary discussion with gyn-onc and REI regarding fertility-sparing options versus standard care; informed consent must reflect explicit understanding of recurrence risk and surveillance burden.
Board pearl: If a stem mentions "granulosa cell tumor" or "persistent anovulation" alongside vaginal bleeding, think estrogen-driven endometrial hyperplasia or cancer — biopsy the endometrium regardless of the adnexal pathology.
Step 3 management: When uncertain, the answer is almost always either (a) endometrial biopsy for diagnosis or (b) refer to gynecologic oncology for management — these are the two highest-yield action items across question patterns.
Endometrial cancer is the leading gynecologic malignancy in the US, presents most commonly as postmenopausal bleeding, is diagnosed by endometrial biopsy, and is surgically staged with TH/BSO + sentinel lymph node mapping — with universal MMR testing now standard to identify Lynch syndrome and to guide immunotherapy.
Board pearl: When a Step 3 stem features postmenopausal bleeding, the highest-yield two-step answer remains: (1) endometrial biopsy to diagnose, then (2) refer to gynecologic oncology for staging and management — and never forget MMR testing to unlock Lynch syndrome surveillance and immunotherapy eligibility.